There are no FOXO4-DRI before and after photographs of a human being, because no human being has received this peptide in a registered study. ClinicalTrials.gov lists no interventional trial of it in people. Any transformation image you find attached to the name is either unattributed, borrowed from something else, or fabricated. That is an unsatisfying answer to the query, so the rest of this page covers what genuinely was photographed and how to read the material circulating.
Key takeaways
- No human before-and-after evidence exists for FOXO4-DRI. Not weak evidence, none.
- The most famous images associated with the compound are of mice, specifically fur regrowth in aged animals.
- A rodent healthspan endpoint is not a human transformation, and the visual similarity is what makes the confusion so easy.
- No timeline can be given honestly, because no human outcome has ever been measured on any timescale.
- Anecdotal reports describe material of unverified composition and cannot separate the compound from everything else a person is doing.
The vendor we point lifters to
FOXO4-DRI from Ascension Peptides
Independently assayed material, dispatched from the US. The vial drops by half with the code below.
One vial size only, so there is no bulk-tier price break to chase on a single order. Per-mg is quoted at the labelled 10 mg: the two published batch reports measured 11.41 mg and 8.30 mg, so the real figure moves with the batch. Buying 3, 5 or 10 takes 3%, 5% or 10% off. Free shipping starts at $250. The vendor spells the product FOX04 with a zero, including in the link above.
- Batch-specific third-party lab report
- Free delivery above $250
- Same-day dispatch on orders before 2pm CST
Research material, laboratory use only, not for human consumption. FOXO4-DRI is not an approved medicine anywhere and has never been tested in a human trial. Affiliate links: we may earn a commission at no extra cost to you. Pricing verified September 2, 2026.
FOXO4-DRI before and after: what was actually photographed
The imagery genuinely associated with FOXO4-DRI comes from Baar and colleagues, Cell, 2017, and it is of mice.
The study reported that treated animals, both the fast-ageing XpdTTD/TTD strain and naturally aged mice, showed restored fur density. That is a visible, photographable change, and images of treated versus untreated animals circulated widely when the paper was covered in the general press. The same work reported restored fitness, measured through physical performance, and improved renal function measured biochemically.
Those are real results and the photographs are real photographs. They document a mouse coat becoming denser. They do not document a human anything.
The distance between the two is larger than it looks. Fur density in a laboratory mouse is a convenient visible proxy for tissue health in an animal with a defined genetic background, a controlled diet, a controlled environment and a short lifespan. It was chosen as an endpoint because it is measurable and meaningful in that model, not because it corresponds to a human outcome anyone cares about.
Why the query has no honest answer in its own terms
Consider what a legitimate before-and-after would require: a person, a defined dose, a defined interval, a measured outcome, and ideally a comparison group. Every element is missing.
There is no defined dose, because no human dose has been established. There is no expected interval, because no human pharmacokinetics exist and nobody knows how long the peptide persists in a person or how long any effect might take to appear. There is no validated outcome measure, because the outcomes used in the animal work, senescent-cell burden imaged by a bioluminescent reporter, fur density, renal markers, are not things a person can assess at home. And there is no comparison group, so even a genuine individual change could not be attributed to the compound.
This is why the page cannot offer a timeline. Not because the information is being withheld, but because producing one would mean inventing it.
How to read what is circulating
Material presented as FOXO4-DRI results falls into a few recognisable categories, and they can be told apart.
| What you encounter | What it usually is | How to check |
|---|---|---|
| Dramatic transformation photos | Reused images, often from unrelated fitness or cosmetic content | Reverse image search, look for the original context |
| Mouse comparison images | Genuine, from the 2017 paper | Trace to the published figure rather than the blog reposting it |
| "Week 4 results" timelines | Authored content with no study behind it | Ask what was measured and by whom |
| Forum accounts | Unverified material, uncontrolled circumstances | Note what else the person was doing simultaneously |
| Clinic marketing | Promotion of an unapproved compound | No clinic can lawfully dispense it |
The forum category deserves particular scepticism, and not because the people writing are dishonest. Someone experimenting with an unapproved research peptide is typically also training, changing diet, sleeping differently and often using several compounds at once. Attributing a change to one variable in that setting is not possible even with good faith on all sides. Add material of unverified identity and composition and there is nothing left to learn from.
The claim this site sees most often
Because this is a body-composition site, the version of the question arriving here usually concerns muscle: whether FOXO4-DRI produces a visible change in lean mass or physique.
It does not, and there is no ambiguity about this. FOXO4-DRI is a senolytic. It does not act on myostatin, activin or follistatin signalling, does not stimulate protein synthesis, and has never been evaluated against a hypertrophy, strength or body-composition endpoint in any organism, including mice. There is no study to report a null result from, because the experiment has not been run.
The legitimate connection between senolytics and muscle is a maintenance argument: senescent cells accumulate in ageing muscle, their inflammatory secretions are implicated in declining satellite-cell function, and clearing them is a plausible way to address that. Plausible is doing real work in that sentence. It is a hypothesis with preclinical support in other tissues, not a demonstrated outcome, and certainly not a visible one. Readers looking for compounds with an anabolic rationale should be reading the muscle-growth peptide guide instead.
What would need to change
For a genuine human before-and-after to exist, the compound would need to complete preclinical toxicology, then a phase 1 trial establishing tolerability and pharmacokinetics, then a trial designed around an outcome measured against a control group. That work has not started.
There is also a reason such a trial would need to be careful rather than merely slow. A 2023 study in Circulation found that clearing senescent cells could worsen pulmonary hypertension, which is a reminder that the effects of senolysis are not uniformly in the direction people expect.
Frequently asked questions
Are there real FOXO4-DRI before and after pictures?
Of mice, yes, from the 2017 Cell paper showing restored fur density in aged animals. Of humans, no. No person has received this peptide in a registered study, so no human before-and-after documentation exists.
How long until results appear?
There is no answer to give. No human outcome has been measured on any timescale, and no human pharmacokinetic data exists to reason from. Any timeline you find was authored rather than observed.
Why do some sites show transformation photos anyway?
Because the query attracts traffic and images are easy to source from elsewhere. Reverse image searching usually locates the original context, which is frequently unrelated fitness or cosmetic content.
Will FOXO4-DRI visibly change my physique?
There is no evidence that it affects body composition at all. It is not anabolic, has no action on muscle-growth pathways, and no study in any species has measured muscle size or strength as an outcome.